News

Lenvima is an orally available tyrosine kinase inhibitor discovered by Eisai. The partnership will jointly develop and commercialize Lenvima as monotherapy and in combination with Merck’s anti-PD-1 therapy

Other investors Oriza Seed Capital, Yipu Capital, AVICT Global Holdings, and existing investors WuXi AppTec Group, and Juno Therapeutics also took part in the funding round. JW Therapeutics

Under the terms of the agreement, Ligand will receive upfront license fees, and is eligible to receive clinical and regulatory milestone payments as well as sales-based milestone payments

The Pharma giant expanded alliance with Science 37 to advance virtual clinical trials program. The trials will be a mix of virtual and traditional models and will have increasing

Under the terms of the agreement, Caladrius acquired the exclusive worldwide rights to the data set and regulatory filings for the CD34+ cell therapy program for the treatment

These trials will evaluate the effect of Jardiance on exercise ability and heart failure symptoms in people with chronic heart failure independent of whether they have type 2

The regulator approved Opdivo label update offering flexible flat-dosing options every two weeks (240 mg) or every four weeks (480 mg). Opdivo, which is a programmed death-1 (PD-1) inhibitor, was

The submission acceptance is based on Phase III data from the DEPICT (Dapagliflozin Evaluation in Patients with Inadequately Controlled Type 1 Diabetes) clinical programme for Forxiga in T1D.

The multi-year collaboration is focused on the identification and development of unique small molecules against targets for a range of oncology, inflammatory and neurodegenerative indications. The collaboration is